7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Osteitis D010000 10 associated lipids
Coronary Disease D003327 70 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Hip Fractures D006620 2 associated lipids
Osteolysis D010014 8 associated lipids
Hypothyroidism D007037 32 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Hamzei M et al. Osteoclast stimulating and differentiating factors in human cholesteatoma. 2003 Laryngoscope pmid:12616193
Shipman CM and Croucher PI Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. 2003 Cancer Res. pmid:12615702
Fahrleitner A et al. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. 2002 Wien. Klin. Wochenschr. pmid:12602117
Stajszczyk M [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. 2002 Pol. Arch. Med. Wewn. pmid:12600190
Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. 2003 J. Immunol. pmid:12594294
Lanzi R et al. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. 2003 Eur. J. Endocrinol. pmid:12590637
Fahrleitner A et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. 2003 Bone pmid:12584041
Gordeladze JO and Reseland JE A unified model for the action of leptin on bone turnover. 2003 J. Cell. Biochem. pmid:12577304
Rifas L et al. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. 2003 J. Cell. Biochem. pmid:12577299
Yu Q et al. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. 2003 J. Immunol. pmid:12574344
Clohisy JC et al. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. 2003 J. Orthop. Res. pmid:12568950
Johnson-Pais TL et al. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. 2003 J. Bone Miner. Res. pmid:12568416
Cao J et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. 2003 J. Bone Miner. Res. pmid:12568404
Xing L et al. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. 2003 J. Bone Miner. Res. pmid:12568403
Buckley KA and Fraser WD Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. 2002 Ann. Clin. Biochem. pmid:12564836
Kanematsu M et al. [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. 2000 Biol. Sci. Space pmid:12561872
Body JJ et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. 2003 Cancer pmid:12548591
Demers LM Bone markers in the management of patients with skeletal metastases. 2003 Cancer pmid:12548589
Lipton A Bisphosphonates and metastatic breast carcinoma. 2003 Cancer pmid:12548585
Croucher PI et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. 2003 Cancer pmid:12548581
Oyajobi BO and Mundy GR Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. 2003 Cancer pmid:12548580
Sordillo EM and Pearse RN RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003 Cancer pmid:12548579
Kato I et al. TRANCE together with IL-7 induces pre-B cells to proliferate. 2003 Eur. J. Immunol. pmid:12548564
Vanderkerken K et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. 2003 Cancer Res. pmid:12543775
Clohisy D Cellular mechanisms of osteolysis. 2003 J Bone Joint Surg Am pmid:12540662
Katavić V et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. 2003 J. Immunol. pmid:12538719
Kanematsu M et al. [Effects of gravity on the gene expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor]. 1999 Biol. Sci. Space pmid:12532992
Woo KM et al. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. 2002 Exp. Mol. Med. pmid:12526098
Berenson JR Advances in the biology and treatment of myeloma bone disease. 2002 Semin. Oncol. pmid:12520479
Spyrou P et al. Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. 2002 Clin Oral Implants Res pmid:12519337
Takayanagi H [Cross-talk between immune and skeletal systems]. 2002 Nippon Rinsho pmid:12510352
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. 2003 Am. J. Hematol. pmid:12508266
Sabokbar A et al. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. 2003 J. Orthop. Res. pmid:12507582
Lee Y et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. 2003 J. Orthop. Res. pmid:12507581
Chagraoui H et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. 2003 Blood pmid:12506018
Bengtsson AK and Ryan EJ Immune function of the decoy receptor osteoprotegerin. 2002 Crit. Rev. Immunol. pmid:12498383
Choi BK et al. Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. 2003 Infect. Immun. pmid:12496170
Toraldo G et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. 2003 Proc. Natl. Acad. Sci. U.S.A. pmid:12490655
Golmia RP et al. Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. 2002 Arthritis Rheum. pmid:12483748
Bolon B et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. 2002 Arthritis Rheum. pmid:12483715
McCauley LK and Nohutcu RM Mediators of periodontal osseous destruction and remodeling: principles and implications for diagnosis and therapy. 2002 J. Periodontol. pmid:12479643
Buckley KA et al. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. 2002 Bone pmid:12477572
Avbersek-Luznik I et al. Increased levels of osteoprotegerin in hemodialysis patients. 2002 Clin. Chem. Lab. Med. pmid:12476941
Hasegawa T et al. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. 2002 J. Periodont. Res. pmid:12472833
Cho CH and Nuttall ME Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. 2002 Expert Opin. Ther. Targets pmid:12472380
Liu D et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. 2003 Int. J. Mol. Med. pmid:12469211
Shimizu-Ishiura M et al. Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. 2002 J Electron Microsc (Tokyo) pmid:12455916
Yamashita T et al. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. 2002 Endocrinology pmid:12446599
Bolon B et al. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. 2002 Cell. Mol. Life Sci. pmid:12440777
Liegibel UM et al. Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. 2002 J. Exp. Med. pmid:12438430
Hofbauer LC and Schoppet M Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12432053
Crotti TN et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. 2002 Ann. Rheum. Dis. pmid:12429533
Lubberts E et al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. 2002 Arthritis Rheum. pmid:12428250
Stejskal D et al. Osteoprotegerin and bone density. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426776
Stejskal D et al. Osteoprotegerin, RANK, RANKL. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426773
Sezer O et al. RANK ligand and osteoprotegerin in myeloma bone disease. 2003 Blood pmid:12424190
Hu Y and Yu S Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. 2002 Zhonghua Bing Li Xue Za Zhi pmid:12419159
Zhao S et al. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. 2002 J. Bone Miner. Res. pmid:12412815
Hegedus D et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. 2002 J. Bone Miner. Res. pmid:12412803
Roodman GD Role of the bone marrow microenvironment in multiple myeloma. 2002 J. Bone Miner. Res. pmid:12412796
Yamada T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 Blood pmid:12411305
Jung K et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. 2002 Jul-Sep Int. J. Biol. Markers pmid:12408468
Okada Y et al. Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. 2002 Endocr. J. pmid:12402981
Liao EY et al. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. 2002 J. Endocrinol. Invest. pmid:12398237
Giuliani N et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. 2002 Blood pmid:12393684
Cremer I et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. 2002 Blood pmid:12393586
Nagasawa T et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. 2002 Clin. Exp. Immunol. pmid:12390325
Suda T et al. [Merger of bone biology and immunology]. 2002 Tanpakushitsu Kakusan Koso pmid:12385106
Abrahamsen B et al. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. 2003 Calcif. Tissue Int. pmid:12384814
Gravallese EM Bone destruction in arthritis. 2002 Ann. Rheum. Dis. pmid:12379632
Jones DH et al. Role of RANKL and RANK in bone loss and arthritis. 2002 Ann. Rheum. Dis. pmid:12379618
David JP et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. 2002 J. Cell. Sci. pmid:12376563
Rude RK et al. Magnesium deficiency: effect on bone and mineral metabolism in the mouse. 2003 Calcif. Tissue Int. pmid:12370796
Romas E et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. 2002 Am. J. Pathol. pmid:12368214
Rogers A et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. 2002 J. Clin. Endocrinol. Metab. pmid:12364420
Fu Q et al. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. 2002 J. Biol. Chem. pmid:12364326
Palenzuela L et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. 2002 J. Med. Genet. pmid:12362049
Yang SY et al. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. 2002 Arthritis Rheum. pmid:12355500
pmid:12354528
Standal T et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. 2002 Blood pmid:12351414
Lee SW et al. TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. 2002 J. Biochem. Mol. Biol. pmid:12296995
Kazama JJ et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. 2002 Nephrol. Dial. Transplant. pmid:12271009
Ferrer Cañabate J et al. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]. 2002 An Med Interna pmid:12244784
Williamson E et al. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. 2002 J. Immunol. pmid:12244151
Hofbauer LC et al. High bone density due to a mutation in LDL-receptor-related protein 5. 2002 N. Engl. J. Med. pmid:12240686
Kudo O et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. 2002 J. Pathol. pmid:12237882
Shiotani A et al. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. 2002 Anat. Rec. pmid:12221720
Sandor M et al. A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. 2002 Biomaterials pmid:12219832
Palmqvist P et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. 2002 J. Immunol. pmid:12218157
Rubin J et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. 2002 J. Clin. Endocrinol. Metab. pmid:12213884
Arko B et al. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. 2002 J. Clin. Endocrinol. Metab. pmid:12213850
Hofbauer LC and Schoppet M Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. 2002 J. Clin. Endocrinol. Metab. pmid:12213849
Kondo H et al. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. 2002 J. Bone Miner. Res. pmid:12211438
Hofbauer LC et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. 2002 J. Cell. Biochem. pmid:12210731
Sedger LM et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. 2002 Eur. J. Immunol. pmid:12209637
Jono S et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. 2002 Circulation pmid:12208791
Juji T et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. 2002 J. Bone Miner. Metab. pmid:12203031
Fujita T et al. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. 2002 J. Oral Pathol. Med. pmid:12201246
Lee SK et al. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. 2002 J. Immunol. pmid:12193704

Table of Content